All In MedTech

FDA Clearance Tracker · P240033

LungFX™ device

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 22, 2026

Approved

Time to decision

630 days

Received Sep 30, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P240033
Device name
LungFX™ device
Applicant location
Silver Spring, MD
Received
Sep 30, 2024
Decided
Jun 22, 2026
Decision
Approved
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code PHO

FDA's approval statement

As written in FDA's record.

This device (“LungFX”) is indicated for centralized, ex vivo (outside the body) evaluation of deceased-donor lungs (single and double) that cannot be placed for transplantation by an Organ Procurement Organization (OPO) with any of the matched candidates if using direct-to-recipient procurement and preservation procedures. LungFX provides normothermic perfusion and ventilation of procured donor lungs initially stored with cold static preservation solution.LungFX is intended to allow for re-assessment, in a controlled environment, of procured donor lungs’ suitability for transplantation into male and female patients aged 18 years or older with end-stage lung disease awaiting first time (double or single) lung transplantation. Lungs accepted for transplantation after LungFX require a second period of storage with cold static preservation solution, and cumulative preservation time of transplanted lungs is not intended to exceed 20 hours.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PHO. The earliest in FDA's data is P180014, decided Apr 26, 2019.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Lung Bioengineering, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.